Asset
Trofinetide
ACADIA Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04988867 | phase2_3 | terminated | 2021-09-22 | 2023-05-31 | ACADIA Pharmaceuticals Inc. | An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome |
| NCT04776746 | phase3 | terminated | 2020-11-08 | 2023-06-30 | ACADIA Pharmaceuticals Inc. | Open-Label Extension Study of Trofinetide for Rett Syndrome |
| NCT04279314 | phase3 | completed | 2020-01-29 | 2022-08-19 | ACADIA Pharmaceuticals Inc. | Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome |
| NCT04181723 | phase3 | completed | 2019-11-06 | 2021-10-28 | ACADIA Pharmaceuticals Inc. | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢) |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 217026 | NDA | ACADIA PHARMACEUTICALS INC |
| NDA 219884 | NDA | ACADIA PHARMACEUTICALS INC |
Marketed products (6)
- DAYBUE
- DAYBUE STIX
- DAYBUE STIX
- DAYBUE STIX
- DAYBUE STIX
- DAYBUE STIX